Method of Developing a Peptide-Based Vaccine Conjugated with 1V209
AssigneeVersitech Limited
InventorsJiandong HUANG, Yefan HU
Life of this patent
Estimating the term…
Abstract
Provided are a composition comprising a peptide conjugated to a TLR agonist, including TLR7 agonist 1v209, and methods of using the composition. The methods comprise administering the peptide-based vaccine conjugate to a subject. The peptide-based vaccine conjugate inhibits tumor growth and induces antigen-specific B and T cell responses in a subject.
Claims20
A peptide-based vaccine conjugate comprising a Toll-like receptor 7 agonist conjugated to a peptide, wherein the Toll-like receptor 7 agonist is 1V209
A composition comprising a peptide-based vaccine conjugate, wherein the peptide-based vaccine conjugate is according to formula (I):
A method of inhibiting tumor growth in a subject, the method comprising administering an effective amount of a peptide-based vaccine conjugate comprising a Toll-like receptor 7 agonist conjugated to a peptide, wherein the Toll-like receptor 7 agonist is 1V209.
Dependencies are inferred from the claim text.